Earnings before Interest, Tax, Depreciation and Amortization (EBITDA)
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).
The financial trajectory from 2016 to 2020 is characterized by a period of significant growth followed by a notable contraction in the final year. Profitability metrics peaked in 2019 across all measured indicators before experiencing a synchronized decline in 2020.
- EBITDA Performance Trends
- Earnings before interest, tax, depreciation and amortization grew substantially from 735 million US$ in 2016 to a peak of 1,358 million US$ in 2019. A sharp increase was observed between 2016 and 2017, where the value rose by approximately 68%. Although a slight dip occurred in 2018, the metric recovered to reach its highest point in 2019 before falling to 1,092 million US$ in 2020.
- Operational Profitability and Depreciation
- A consistent gap is maintained between EBITDA and EBIT, reflecting the impact of depreciation and amortization. This difference expanded from 141 million US$ in 2016 to 188 million US$ in 2019, suggesting an increase in the company's asset base or amortization requirements over time. The operational profitability, as measured by EBIT, mirrored the EBITDA trend, peaking at 1,170 million US$ in 2019.
- Net Income and Bottom-Line Correlation
- Net income attributable to stockholders exhibited a more linear growth pattern than EBITDA between 2016 and 2019, rising from 463 million US$ to 1,002 million US$. However, the decline in 2020 was more severe for net income, which dropped to 656 million US$, representing a more significant percentage decrease than that observed in the EBITDA figure for the same period.
- Comparative Earnings Volatility
- While EBT and EBIT showed relative stability between 2017 and 2019, the 2020 results indicate a broad compression of margins. The reduction in EBITDA from 1,358 million US$ to 1,092 million US$ suggests a decrease in core operational cash flow generation during the final year of the analyzed period.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Enterprise Value to EBITDA Ratio, Current
| Selected Financial Data (US$ in millions) | |
| Enterprise value (EV) | 61,504) |
| Earnings before interest, tax, depreciation and amortization (EBITDA) | 1,092) |
| Valuation Ratio | |
| EV/EBITDA | 56.32 |
| Benchmarks | |
| EV/EBITDA, Competitors1 | |
| AbbVie Inc. | 33.09 |
| Amgen Inc. | 17.60 |
| Bristol-Myers Squibb Co. | 10.65 |
| Danaher Corp. | 25.51 |
| Eli Lilly & Co. | 47.82 |
| Gilead Sciences Inc. | 16.86 |
| Johnson & Johnson | 16.70 |
| Merck & Co. Inc. | 14.28 |
| Pfizer Inc. | 13.43 |
| Regeneron Pharmaceuticals Inc. | 15.48 |
| Thermo Fisher Scientific Inc. | 25.08 |
| Vertex Pharmaceuticals Inc. | 27.77 |
Based on: 10-K (reporting date: 2020-12-31).
1 Click competitor name to see calculations.
If the company EV/EBITDA is lower then the EV/EBITDA of benchmark then company is relatively undervalued.
Otherwise, if the company EV/EBITDA is higher then the EV/EBITDA of benchmark then company is relatively overvalued.
Enterprise Value to EBITDA Ratio, Historical
| Dec 31, 2020 | Dec 29, 2019 | Dec 30, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Enterprise value (EV)1 | 69,822) | 41,239) | 41,525) | 31,596) | 23,847) | |
| Earnings before interest, tax, depreciation and amortization (EBITDA)2 | 1,092) | 1,358) | 1,130) | 1,236) | 735) | |
| Valuation Ratio | ||||||
| EV/EBITDA3 | 63.94 | 30.37 | 36.75 | 25.56 | 32.43 | |
| Benchmarks | ||||||
| EV/EBITDA, Competitors4 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).
3 2020 Calculation
EV/EBITDA = EV ÷ EBITDA
= 69,822 ÷ 1,092 = 63.94
4 Click competitor name to see calculations.
The financial trajectory from 2016 to 2020 is characterized by a substantial expansion in enterprise value that significantly outpaced the growth of operational earnings, resulting in a sharp increase in the valuation multiple by the end of the period.
- Enterprise Value (EV) Trends
- A consistent upward trend in enterprise value is observed, rising from 23,847 million US$ in 2016 to 69,822 million US$ by 2020. The growth was relatively steady between 2016 and 2019, followed by a precipitous increase in 2020, where the value grew by approximately 69% in a single year.
- EBITDA Performance
- Earnings before interest, tax, depreciation, and amortization exhibited volatility over the five-year span. After an initial increase from 735 million US$ in 2016 to 1,236 million US$ in 2017, EBITDA experienced a slight contraction in 2018, recovered to a peak of 1,358 million US$ in 2019, and subsequently declined to 1,092 million US$ in 2020.
- EV/EBITDA Multiple Analysis
- The EV/EBITDA ratio demonstrates significant fluctuation, reflecting a decoupling of market valuation from operational cash flow. The ratio declined from 32.43 in 2016 to a low of 25.56 in 2017, before oscillating between 30.37 and 36.75 through 2019. A dramatic escalation occurred in 2020, with the ratio peaking at 63.94, more than doubling the previous year's multiple. This surge indicates that the market assigned a substantially higher premium to the enterprise relative to its EBITDA performance during the final year of the analyzed period.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?